Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom

被引:200
|
作者
Ohayon, MM
Lader, MH
机构
[1] Stanford Univ, Sch Med, Stanford Sleep Epidemiol Res Ctr, Stanford, CA 94305 USA
[2] Kings Coll London, Inst Psychiat, London WC2R 2LS, England
关键词
D O I
10.4088/JCP.v63n0912
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: The use of psychotropic medications and its association with sleep and psychiatric and physical illnesses were studied in the general population. Method: A cross-sectional telephone survey was carried out using the Sleep-EVAL knowledge-base system. A representative sample of the noninstitutionalized general populations of France, Germany, Italy, and the United Kingdom, aged 15 years or over, was interviewed (N = 18,679; participation rate: 78.8%; target population: 204,605,391 inhabitants), Questions were asked about psychotropic medication intake (name of medication, indication, dosage, duration of intake, prescriber), sociodemographics, physical illnesses, and DSM-IV mental disorders. Results: At the time of the interview, 6.4% of the subjects took a psychotropic medication. Anxiolytics were reported by 4.3% of the sample, hypnotics by 1.5%, antidepressants by 1.0%, and neuroleptics and other psychotropics by less than 1.0%. Hypnotics and anxiolytics were mostly used as a sleep disorder treatment. Antidepressants were taken appropriately for a depressive illness in only 44.1% of cases. Low doses of hypnotics and anxiolytics were found in about 10% of cases and low doses of antidepressants in 31.7% of cases. Subjects with a psychiatric disorder received a psychotropic treatment only infrequently (between 10% to 40.4%, depending on the disorder). All psychiatric disorders, including mood disorders, were treated mainly with an anxiolytic. A concomitant physical illness increased the likelihood of using a psychotropic treatment and was a strong predictor of adequate psychotropic dosage. Conclusion: Psychiatric pathology and sleep disorders remained mostly untreated or inadequately managed in the general population. Depression is underdiagnosed by the physicians and is treated with antidepressant in only 7% of cases. By contrast, anxiolytics are extensively prescribed, especially in France and Italy. The co-occurrence of organic and psychiatry disorders increases the frequency of medical consultations and the likelihood of being given a prescription for the mental disorder.
引用
收藏
页码:817 / 825
页数:9
相关论文
共 50 条
  • [31] INCIDENCE AND PREVALENCE OF DIAGNOSED AND UNDIAGNOSED HEMOPHILIA A AND HEMOPHILIA B IN THE UNITED KINGDOM, GERMANY, FRANCE, ITALY, AND SPAIN
    Kempel-Waibel, A.
    Chiu, G. R.
    Brouwer, E.
    HAEMOPHILIA, 2020, 26 : 51 - 51
  • [32] Leaving and returning to the parental home during COVID times in France, Italy, Germany, Spain, and the United Kingdom
    Luppi, Francesca
    Rosina, Alessandro
    Sironi, Emiliano
    DEMOGRAPHIC RESEARCH, 2024, 50 : 101 - 114
  • [33] Treatment patterns and outcomes in patients with metastatic synovial sarcoma in France, Germany, Italy, Spain and the United Kingdom
    Patel, Nashita
    Pokras, Shibani
    Ferma, Jane
    Casey, Vicky
    Manuguid, Fil
    Culver, Ken
    Bauer, Sebastian
    FUTURE ONCOLOGY, 2023, 19 (18) : 1261 - 1275
  • [34] Types of discourse disseminated by food influencers: Trends on Instagram in France, Germany, Italy, Spain, and the United Kingdom
    Von-Polheim, Paula
    Cano-Oron, Lorena
    Vengut-Climent, Empar
    PROFESIONAL DE LA INFORMACION, 2023, 32 (06):
  • [35] Divergent Interests and Different Success Rates: France, Germany, Italy, and the United Kingdom in EU Legislative Negotiations
    Torsten J Selck
    Michael Kaeding
    French Politics, 2004, 2 (1) : 81 - 95
  • [36] Food taxation in the United Kingdom, France, Germany, and the United States.
    Rosenbaum, S
    JOURNAL OF THE ROYAL STATISTICAL SOCIETY, 1908, 71 : 319 - 365
  • [37] OFF LABEL USE OF INTRAVENOUS IMMUNOGLOGULINS (IVICS): FUNDING MECHANISMS IN FRANCE, GERMANY, ITALY, SPAIN AND THE UNITED KINGDOM (EU5)
    Charafi, N.
    Darnis, Gauthier M.
    Conti, C. C.
    VALUE IN HEALTH, 2015, 18 (07) : A552 - A552
  • [38] EPIDEMIOLOGY OF EYE DISORDERS DUE TO THE USE OF VIDEO DISPLAY TERMINALS IN FRANCE, GERMANY, ITALY, SPAIN AND UNITED KINGDOM - A SYSTEMATIC LITERATURE REVIEW
    Pagidigummula, R.
    Yadav, H.
    Kaur, D.
    Verma, A.
    Kataria, A.
    Goyal, R.
    Aggarwal, A.
    VALUE IN HEALTH, 2022, 25 (12) : S229 - S229
  • [39] Psychotropic medication use in children and adolescents:: A study from France
    Sevilla-Dedieu, Christine
    Kovess-Masfety, Viviane
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2008, 18 (03) : 281 - 289
  • [40] HEALTH-RELATED QUALITY OF LIFE (HRQOL) MEASURED BY PROMIS PREFERENCE SCORE (PROPR) IN THE GENERAL POPULATION OF THE UNITED KINGDOM, FRANCE, AND GERMANY
    Klapproth, C.
    Gibbons, C.
    Valderas, J. M.
    Leplege, A.
    Rose, M.
    Fischer, F.
    VALUE IN HEALTH, 2019, 22 : S830 - S830